Value-based care & compensation | Shockwave’s IVL tech gains new FDA approval | Vaccination for high-risk patients

Compensation for cardiologists has been ample in recent years. Could the healthcare industry’s growing interest in value over volume lead to a change in that trend?

Shockwave Medical announced Tuesday, Feb. 16, that intravascular lithotripsy (IVL) has gained FDA approval for the treatment of severely calcified coronary artery disease.

According to the new recommendation, patients with advanced cardiovascular disease are at an especially high risk of COVID-related complications and need to be vaccinated as quickly as possible. 

Some COVID-driven changes will likely remain in place for years to come, according to a presentation at CV Summit Virtual 2021.

According to a new study published in Circulation, ablation was associated with numerous benefits over standard drug therapy.

The donation will go toward helping physician assistants and nurse practitioners further their careers. 

The investigation was retrospective, but Duke scientists believe their algorithm could potentially aid radiologists in spotting near-misses in their work.

An AI startup’s virtual-patient technology is good enough at teaching empathy to clinicians that it’s already in use at Cedars-Sinai Medical Center in Los Angeles, the National Health Service in Britain and the University of Texas Medical Branch in Galveston.